For Research Use Only. We do not provide direct services or products for patients.
Product Overview
SARS-CoV-2 Hybrid alphavirus-pseudovirus-(B.1.494) (LacZ) was prepared by co-transfecting HEK293T cells with an alphavirus-based vector and a plasmid containing the SARS-CoV-2 all 4 structural proteins (S, M, N, and E) encoding gene. The packaged hybrid alphavirus pseudovirus expresses full-length S, M, N, and E proteins and carries a reporter genome derived from an alphavirus-based vector, which can be used to infect cells, and express reporter gene in the cells to characterize the infectivity of the virus.
Product Type
Pseudovirus
Target
SARS-CoV-2
Contents
Contains SARS-CoV-2-(-B.1.494) S, M, N, and E proteins full-length gene.
Backbone
Alphavirus vector
Reporter Gene
LacZ
Variant
B.1.494
Applications
Neutralizing antibodies screening; Quantification; Drug screening; Identification
Storage
Store at -20°C
Introduction
The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.